NCT03444584 - Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

December 6, 2018

Study Completion Date

December 6, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MEDI0382

Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).

DRUG

Placebo

Subcutaneous dose of placebo matched to MEDI0382.

DRUG

Dapaglifozin

Oral dose of dapaglifozin 10 mg tablet.

DRUG

Metformin

Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).

Trial Locations (8)

Research Site, Miskolc

Research Site, Szeged

Research Site, Balatonfüred

Research Site, Magdeburg

Research Site, Mannheim

Research Site, München

Research Site, Manchester

Research Site, Rotherham